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Peptidylglycine alpha-amidating monooxygenase (PAM) catalyzes the COOH-terminal amidation of peptide hormones. We previously had
found high expression of PAM in several regions of the developing rodent. To determine the function of PAM during mouse embryogenesis, we
produced a null mutant of the PAM gene. Homozygous mutants die in utero between e14.5 and e15.5 with severe edema that is likely due to
cardiovascular deficits. These defects include thinning of the aorta and carotid arteries and are very similar to those of the recently characterized
adrenomedullin (AM) gene KO despite the presence of elevated immunoreactive AM in PAM KO embryos. No peptide amidation activity was
detected in PAM mutant embryos, and there was no moderation of the AM-like phenotype that could be expected if any alternative peptide
amidation mechanism exists in the mouse. Despite the proposed contribution of amidated peptides to neuronal cell proliferation, no alteration in
neuroblast proliferation was observed in homozygous mutant embryos prior to lethality. Mice heterozygous for the mutant PAM allele develop
normally and express wildtype levels of several amidated peptides despite having one half the wildtype levels of PAM activity and PAM protein.
Nonetheless, both an increase in adiposity and a mild glucose intolerance developed in aged (>10 months) heterozygous mice compared to
littermate controls. Ablation of PAM thus demonstrates an essential function for this gene during mouse development, while alterations in PAM
activity in the adult may underlie more subtle physiologic effects.
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The formation of biologically active peptide hormones is a
multistep process beginning with the synthesis of large inactive
pre-proproteins. These precursors are first proteolytically
cleaved at dibasic consensus sequences by a family of
prohormone convertases (PCs) (reviewed in Steiner, 1998;
Seidah and Chretien, 1999). The COOH-terminal basic
residues exposed by these cleavages are then removed by
carboxypeptidases (CPs). If a glycine residue is exposed during
this process, it can serve as a substrate for the amidation
reaction. This final posttranslational processing step is cata-0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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(PAM). In mammals, amidation activity is thought to be
encoded by a single gene product containing two enzymatic
domains, peptidylglycine a-hydroxylating monooxygenase
(PHM) and peptidyl-a-hydroxyglycine a-amidating lyase
(PAL), that act sequentially to amidate peptides (Prigge et al.,
2000).
Peptide amidation is often required to confer full biological
activity to a peptide because the presence of an amide group
can significantly increase the affinity of the peptide for its
receptor and can also extend peptide half-life (Cuttitta, 1993;
Merkler, 1994), possibly by stabilizing its secondary structure
(In et al., 2001). PAM substrates are numerous and include
neuroendocrine hormones and neurotransmitters such as
gonadotropin-releasing hormone (GnRH), adrenomedullin
(AM), neuropeptide Y (NPY), and cholecystokinin (CCK)
(Bradbury and Smyth, 1987; Eipper et al., 1992; Merkler,87 (2005) 301 – 313
www.e
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peptides, with kinetic parameters determined by the penulti-
mate residue.
Amidated peptides are abundant in both vertebrates and
invertebrates such as Cnidarians (Grimmelikhuijzen et al.,
1996), Aplysia (Kaldany et al., 1985) and Drosophila (Nassel,
1999; Taghert, 1999). Over 90% of neuropeptides in Drosoph-
ila are predicted to be amidated (Kolhekar et al., 1997b), while
at least half of all biologically active peptides in mammals are
amidated (Eipper et al., 1992). Amidated peptides contribute to
processes as diverse as glucose homeostasis (Drucker, 2002),
skeletal development (Karaplis et al., 1994), weight regulation
(Cupples, 2002; Gundlach, 2002), cardiovascular (CV) func-
tion (Eto and Samson, 2001), cell proliferation and cell survival
(Hansel et al., 2001a,b). Several amidated peptides are present
during development including adrenomedullin (AM) (Mon-
tuenga et al., 1997), parathyroid hormone-related peptide
(PTHrp) (Lee et al., 1995) and pituitary adenylate cyclase-
activating polypeptide (PACAP) (Shuto et al., 1996), suggest-
ing that these amidated peptides have particularly important
functions during embryogenesis as well as in the adult. PAM
expression is widespread in the adult CNS and is highest in the
hypothalamus, hippocampus and pituitary (Braas et al., 1989;
Schafer et al., 1992). PAM is also expressed in several
peripheral tissues including the heart, lungs, adrenal gland
and pancreas (Braas et al., 1992). In general, the expression
pattern of PAM in both the adult and developing embryo
corresponds well with the expression patterns of amidated
substrates. However, PAM has not been detected in the PP cells
of the endocrine pancreas (Martinez et al., 1993a) or the
epithelial cells of the small intestine (Martinez et al., 1993b)
where amidated peptides have been found. These findings
raised the possibility that an alternative amidation mechanism
may exist.
In the developing rodent, there is early and widespread
expression of PAM (Zhang et al., 1997) implicating PAM (and
thus amidated peptides) in important roles in embryogenesis.
The highest expression of PAM in the embryo proper begins in
the heart by e9. High expression of PAM in the heart continues
throughout embryogenesis, suggesting that PAM has an
important role in embryonic cardiac development and function.
PAM is also highly expressed in the ventricular zone regions
and mantle layers of multiple CNS regions as early as e12.5
where it could potentially regulate neuronal cell proliferation
and differentiation. PAM is expressed at moderate levels in
peripheral structures such as the gut and in developing tooth
and limb buds. Taken together, these expression patterns
implicate PAM in multiple developmental processes. Lastly,
expression of PAM in uterine cells as early as e6 suggests that
PAM could function in normal pregnancy.
A mutation of the PHM gene in Drosophila results in
lethality at midgestational stages (Kolhekar et al., 1997b).
However, since PHM and PAL enzymatic activities are
encoded by separate genes in Drosophila (Kolhekar et al.,
1997b; Jiang et al., 2000) and at least two copies of PAL have
been found in its genome (Han et al., 2004), Drosophila is
likely not a good model to predict PAM function in vertebrates.Inhibitors of PAM have been used to examine tissue-specific
functions of PAM in the adult (Mueller et al., 1993; Ogonowski
et al., 1997), but lack of specificity and efficacy has limited
their utility. Mouse models of copper deficiency (Grimes et al.,
1997; Kuo et al., 2001; Steveson et al., 2003), which have
reduced amounts of PAM enzymatic activity, exhibit severe
developmental phenotypes. However, many enzymes in
addition to PAM require copper to function, and these mice
would be expected to have multiple defects unrelated to any
decrease in PAM activity. The early ontogeny of PAM, and the
discrete developmental expression patterns of PAM mRNA
transcripts, implicates PAM in multiple functions during
embryogenesis. We therefore made a null mutant of the PAM
gene via traditional gene targeting methods to determine the
function of PAM during development. We have also tested for
the presence of alternative peptide amidating mechanisms in
PAM null mutant mice.
Materials and methods
Gene targeting
PAM knockout (KO) mice were produced by conventional gene targeting
methods. The targeting vector was constructed in two sequential subcloning
steps (Fig. 1). First, a 4.5 kb XbaI fragment 5V of exon 2 (Ouafik et al.,
1992) was subcloned into an XbaI digested pBluescript-based vector
(obtained from Dr. S. Potter, University of Cincinnati) containing both a
neomycin resistance cassette (neor) and the Herpes Simplex Virus thymidine
kinase (HSV-TK) gene. The resulting vector was subsequently digested with
ClaI (blunted), and a 3 kb EcoRI fragment (blunted) 3V of exon 3 was
subcloned into this site. Linearized targeting vector (15 Ag) was electro-
porated into AB2.2 ES cells (Lexicon Genetics, Texas). Targeted ES cells
were identified by genomic Southern blotting using a probe external to the
targeting vector (Fig. 1B) and were microinjected into C57Bl6/J e3.5
blastocysts to generate chimeric mice.
PAM activity assays
Embryos were collected from timed heterozygous matings at e12.5, divided
into heads and trunks, and frozen on dry ice. Placental tissue was saved for use
in genomic Southern blotting. For analysis of adult mice, dissected tissue was
frozen on dry ice and stored at 80-C until use. All tissue was homogenized in
10 volumes of buffer containing NaTES–mannitol–Triton X-100 (TMT) (pH
7.4) and protease inhibitors, as previously described (Kolhekar et al., 1997a).
Protein concentrations were determined using BCA reagent (Pierce). Samples
were diluted 10-fold in PHM diluent and incubated for 1 h in the presence of
125I-Acetyl-Tyr-Val-Gly, Cu+2 and ascorbate (for PHM assays) or 125I-Acetyl-
Tyr-Val-(OH)-Gly (for PAL assays) (Kolhekar et al., 1997a). Uncharged
amidated product was extracted with ethyl acetate and counted. Data were
converted to picomoles per microgram of protein per hour (pmol/Ag protein/h)
and analyzed with unpaired t tests.
Western blot analysis
Tissue was homogenized in 10 volumes of buffer containing TMT and
protease inhibitors, as described for PAM activity assays. Samples were
denatured with Laemmli sample buffer and electrophoresed on 4–15%
polyacrylamide gradient gels. Following electroblotting onto PVDF mem-
branes, membranes were blocked with 5% non-fat milk and incubated with
primary antibody to PAM (Ab 629; 1:2000 for crude serum and 1:200 for
affinity-purified antibody) as previously described (Ciccotosto et al., 2000).
Ab 629 recognizes Exon A (exon 16) of the PAM gene and recognizes full-
length PAM-1 and the monofunctional PHM and PAL products derived
from it. Previous in situ hybridization studies using a probe that is specific
Fig. 1. PAM KO mice generated via gene targeting methods. (A) Shown is the structure of a genomic clone (5V–3V) of the PAM gene containing exons 2 and 3 and
the 0.8 kb intron that separates them. A 2 kb fragment containing these exons was replaced with neor in the targeting vector, which deleted both the translational start
site (exon 2), and also residues (exon 3) required for catalytic activity of PHM. (B) Southern blot analysis of BamHI digested ES cell DNA, screened with a 1 kb
NotI/EcoRI 32P-labeled probe external to the 3V region outside of the targeting vector, yielded a 33 kb fragment for the wildtype allele and a 17 kb fragment for the
mutant allele. (C) Shown are the results of a genomic Southern blot of placental DNA digested with BamHI using the 3V external probe as in panel B and with a 5V
external probe. Embryos were collected from heterozygous matings at e12.5.
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e14.5 in the heart (Zhang et al., 1997) and in adult tissue (Braas et al.,
1992).
Histological analysis of embryos
Embryos were collected from timed heterozygous matings and immediately
submerged in 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS)
and stored at 4-C until being embedded in paraffin wax (Paraplast). Placental
tissue was collected for use in genomic Southern blotting. Transverse sections
of embryos were cut with a microtome (8–10 Am thick).
BrdU immunohistochemistry
Pregnant females were injected with 50 Ag/g BrdU (Sigma) and sacrificed
30 min later. Embryos were then prepared as described for histology. Sections
were treated with 1 mg/ml trypsin (Sigma) dissolved in deionized dH2O for 20
min at 37-C followed by 2 N HCl for 30 min and then blocked with 10% horse
serum/0.1% Tween-20/1 PBS. Sections were then incubated with a sheep
polyclonal BrdU antibody diluted 1:1000 (RDI, Inc. Flanders, NJ) in 5% horse
serum/0.1% Tween-20/1 PBS. The next day, sections were incubated with
biotinylated secondary antibody, treated with ABC reagent (Vector Laborato-
ries) and visualized with DAB (Sigma). It should be noted that only cells
actively synthesizing DNA during the 30-min treatment period would be
labeled with BrdU. Hence, the rate of cell division can be compared between
genotypes using this method.
Cells from several CNS regions were counted from the ventricle to the end
of the ventricular zone (defined as the end of BrdU-labeled cells). The length
along the ventricle that was counted in each section was identical for wildtype
and mutants (approximately 200 Am), allowing for their comparison. Thelabeling index (LI) was the ratio of BrdU-positive cells over the total number of
cells counted multiplied by 100. Data were analyzed using unpaired t tests.
Determination of fasting blood glucose levels and adiposity
Blood glucose levels were determined after a 6-h fast in 2-month- and 10-
month-old male heterozygous and wildtype mice. Blood was collected from the
tail vein, and glucose levels were determined using the Accu-chek Advantage
glucometer (Roche). Blood glucose levels were measured in milligrams per
deciliter (mg/dL) and analyzed with an unpaired t test.
Adiposity was determined as the combined weight of three white adipose
tissue pads (bilateral reproductive, inguinal and retroperitoneal) expressed as a
percentage of body weight T SEM. Adiposity was measured in male 10-month-
old heterozygous and littermate control mice.
Glucose tolerance test
Experimentally naive 2-month- and 10-month-old male heterozygous and
wildtype mice were fasted for 6 h and then given an i.p. injection of 2 mg/g
body weight of d-glucose (Dextrose, Sigma Chemicals). Blood glucose
measurements were taken as described above at 15, 30, 60 and 120 min
post-injection. Data were analyzed with an unpaired t test for each time point.
Radioimmunoassays (RIAs)
To compare the levels of amidated peptide in adult and 3-day-old (p3)
PAM heterozygous mice to that of age-matched wildtype controls, we
performed RIA analysis on pituitary and hypothalamic samples from each
age. Tissue was homogenized in 10% acetic acid/0.5 mg/ml bovine serum
albumin (BSA)/0.3 mg/ml PMSF, lyophilized and resuspended in 50 mM
Table 1
PAM KOs die in utero at e14.5
Age +/+ +/ / Tota
e17.5 5 16 0 21
e15.5 8 (2) 23 (2) 0 (10)a 31
e14.5 13 (1) 35 (10) 21 (2) 69
e13.5 18 (2) 45 (9) 29 (5) 92
e12.5 45 (0) 64 (14) 49 (0) 158
e11.5 27 (1) 40 (7) 14 (2) 81
452
Shown are embryos obtained from timed heterozygous matings. No homozy
gous mutants have been obtained at e15.5 or later. At e14.5 and earlier
wildtypes, heterozygotes and mutants were detected in the expected Mendelian
inheritance ratio of 1:2:1 (totals 103:184:113). Indicated in parenthesis is the
number of resorbed embryos that were collected. Note that there were no
disproportionate numbers of resorbed homozygous mutant embryos collected a
e14.5, indicating that mutants die after this age. The numbers in the last column
are the total number of viable embryos that were collected at each age.
a These embryos were already in the process of being resorbed.
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sample were incubated overnight at 4-C with trace amounts of iodinated
peptide and the appropriate corresponding antibodies: amide-specific alpha
melanocyte-stimulating hormone (a-MSH) Ab Wanda (1:50,000), amide-
specific joining peptide (JP) Ab Jamie (1:2000) (Eipper et al., 1986),
adrenocorticotropic hormone (ACTH) COOH-terminus specific Ab Kathy
(1:2000) (Schnabel et al., 1989; Bruzzaniti et al., 1999; Ciccotosto et al.,
1999), CCK-8 amide-specific Ab 8007 (1:400,000) (generous gift from Dr.
Jens Rehfeld, University of Copenhagen) or NPY mid-region Ab JH3
(1:20,000) (Hansel et al., 2001a). The JH3 antibody recognizes both amidated
and non-amidated forms of NPY. Bound and free peptides were separated by
precipitation with goat anti-rabbit secondary antibody, the supernatant was
discarded, and the amount of 125I in the pellet was counted. Synthetic ACTH
(1–39) (Ciba Pharmaceutical Co., Summit, NJ), a-MSH-NH2 (Bachem), d-
Tyr-joining peptide (12–18)-NH2 (Vega Biotechnologies, Tucson, AZ),
CCK-8-NH2 (Peninsula) and NPY (Bachem) were used to generate standard
curves. Assays for total mouse AM were performed with a kit from Phoenix
Pharmaceuticals (Belmont, CA). PACAP and AM assays were also performed
using peptides and antisera from Bachem (Torrance, CA). Data were analyzed
with unpaired t tests.
ACTH (1–39) is the immediate precursor to a-MSH and corticotropin-like
intermediate lobe peptide (CLIP) and served as an internal control for protein
concentration in each pituitary sample. The amount of total NPY was
determined in each hypothalamic sample and served as a control for variations
in protein levels. Furthermore, all samples from both the pituitary and
hypothalamus were run on polyacrylamide gels, transferred to PVDF
membranes and then stained with Coomassie blue to verify the relative protein
levels and integrity of each sample.
Results
Gene targeting of PAM
Approximately 17% of ES clones screened were heterozy-
gous for the mutant PAM allele. Two clones were used for
microinjection and were also screened by genomic Southern
blotting using a 1.2 kb 32P-labeled neor probe. Only the
predicted 17 kb mutant band was labeled, demonstrating that
there was no random integration of the targeting vector. Four
male chimeras were obtained and mated to C57Bl6/J females.
One targeted ES clone generated a chimera that was 100%
germ-line transmitting and, as expected, transmitted the mutant
PAM allele to 50% of its offspring. Heterozygotes born from
this chimera were mated to obtain all mice analyzed. To
complement analysis of the 3V integration site that used an
external probe for Southern analysis (Figs. 1B, C), the integrity
of the 5V genomic insertion site was also verified by genomic
Southern blotting of BamHI digested DNA from wildtype,
heterozygous and mutant embryos using a 304 bp probe from
the region 5V of the targeting vector (Fig. 1C). Only the
predicted bands of 33 kb and 15 kb were obtained for the
wildtype and mutant samples, respectively.
Production of PAM KOs
Analysis of mice derived from heterozygous matings
revealed that no homozygous mutants were present after birth.
Out of 355 offspring from heterozygous matings genotyped at
3–4 weeks of age, 123 (35%) were wildtype and 232 (65%)
were heterozygous for the mutant PAM allele. Analysis of the
genotypes of embryos collected from timed heterozygous
matings demonstrated that PAM null mutants were presentonly at e14.5 and earlier (Table 1). There was no evidence to
suggest that any of the PAM mutant embryos died before
e14.5. At e14.5 and earlier, PAM mutants were present in
normal Mendelian proportions. Moreover, there was no
increase in the number of resorbed homozygous mutant
embryos collected at this stage as compared to other genotypes
(Table 1). It was therefore concluded that lethality occurred
during a discrete developmental time period between e14.5 and
e15.5.
Morphological and histological analysis of mutant PAM
embryos
By e13.5, all homozygous mutant embryos collected (Table
1) had notable differences in the yolk sac vasculature as
compared to wildtype or heterozygous littermate controls (Figs.
2A, B). In the homozygous mutants, there appeared to be both
the absence of vessels and poorly formed vessels. Furthermore,
the umbilical cord vein in the homozygous mutants always
appeared constricted as compared to littermate controls (Figs.
2C, D). All embryos collected were subsequently dissected out
of the yolk sac and subjected to careful inspection for gross
abnormalities (Table 1). While the gross morphology of mutant
PAM embryos appeared similar to wildtype controls at e11.5
and e12.5 and earlier, all e13.5 and e14.5 (Figs. 2G, J) mutant
embryos had visible edema. Several embryos from e10.5,
e11.5, e12.5, e13.5 and e14.5 were subsequently selected for
histological analysis. One out of two e11.5 mutant embryos and
all three e12.5 mutant embryos that were analyzed already had
fluid accumulation near the aorta and rib primordia (Figs. 3A,
B). Fluid accumulation was also present in all three e13.5
mutant embryos examined, and the amount of fluid had
substantially increased (Figs. 3C, D). At e14.5, the fluid
accumulation in mutant embryos was massive and was now
also clearly seen in the pleural and peritoneal cavities. We were
unable to find morphological abnormalities in aortic and
venous structures of e11.5 mutant embryos, but we did observe
that six out of nine e12.5, e13.5 and e14.5 homozygous mutant
embryos had thinner arterial walls, with the thoracic andl
-
,
t
Fig. 2. As shown in panels A and B, e13.5 PAM mutant embryos lack a well-
developed yolk sac vasculature as compared to wildtype (not shown) or
heterozygous littermate controls. The red arrow points to the umbilical cord
vein in panels C and D. PAM mutant embryos develop severe edema by e14.5
(E–J). Although the gross morphology of e12.5 (E–G) PAM KOs appears
similar to wildtype, by e14.5 (H–J), the edema is visible in all mutant embryos
(J) and is severe. The arrow in panel J points to the skin.
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all affected embryos (Figs. 3E–P). The severe edema in e13.5
and e14.5 homozygous mutant embryos often made analysis
difficult. Several structures, including the aorta, lungs and liver,
were often disfigured by the increasing fluid accumulation. We
did, however, observe a decrease in the thickness of the
epithelial cells of the developing bronchi in the lungs of e14.5
homozygous mutant embryos as compared to wildtype controls
(Figs. 3Q–T) which is consistent with the relatively strongFig. 3. Histological analysis demonstrates edema as well as alterations in the
vasculature and lung of mutant PAM embryos. Mutant PAM embryos have
begun to accumulate fluid as early as e12.5 near the aorta and rib primordium
(B). By e13.5, the amount of fluid has increased (D) and has extended into the
subcutaneous region (denoted by red arrow). Low power images (A–D) were
taken at 16magnification. Also shown are higher-magnification pictures of the
carotid artery (E, H, K, N), the thoracic aorta (F, I, L, O), and the abdominal aorta
(G, J, M, P) in e13.5 (E–J) and e14.5 (K–P) wildtype and homozygous mutant
embryos. Note that the arterial walls are thinner in homozygous mutant embryos
(H–J, N–P). Shown in panels Q–T are low- and high-magnification pictures of
the lungs of e14.5 wildtype and homozygous mutant embryos. The arrows in
panels S and T point to the developing bronchi. Note that the columnar epithelial
cells surrounding the bronchi are smaller in homozygous mutants. The scale bar
in panels E–P and S–T is equal to 100 Am. (Abbreviations are a = accessory
lobe of right lung, c = cranial lobe of right lung, DRG = dorsal root ganglion, l =
left lung, m = middle lobe of right lung, RV = right ventricle.)expression of PAM and AM that has been reported in these
cells (Zhang et al., 1997; Garayoa et al., 2002). Additionally,
we consistently observed an increased density of trabeculae
carneae in the left ventricle of mutant PAM embryos from
e12.5 through e14.5 (Fig. 4). This phenomenon was observed
in two out of three e12.5 mutant embryos and in all three e13.5
and e14.5 homozygous mutant embryos when compared to the
same number of wildtype controls at each stage.
Fig. 4. Trabeculation is increased in the left ventricles of mutant PAM
embryos. Shown are hematoxylin and eosin stained transverse sections of the
whole heart (A, B, E, F, I, J) and higher-magnification of the left ventricle (C,
D, G, H, K, L) from wildtype and mutant PAM embryos at e12.5 (A–D),
e13.5 (E–H), and e14.5 (I–L). While the structure of the whole heart appears
similar to wildtype controls, mutant PAM embryos have an increased density
of trabeculae carneae in the left ventricle (D, H, L). At e14.5, the left ventricle
of mutant PAM embryos is partially occluded (L). The scale bars in all panels
are equal to 100 Am.
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To determine whether there was any alternative amidation
enzymatic activity, PHM and PAL activities were assayed incrude protein extracts of e12.5 embryos. No PHM or PAL
activity above background was detected in PAM homozygous
mutants, suggesting that the sole source of amidation activity
detectable with this assay is the result of the PAM gene product
(Figs. 5A, B). Furthermore, both PHM and PAL activity were
one half the wildtype levels in both the heads and trunks of
heterozygous embryos. These experiments demonstrate that
these assays can successfully detect amidation activity in early
mouse embryos and are consistent with the high and
widespread expression of PAM by e12.5 in both the developing
heart and brain (Zhang et al., 1997). Western blot analysis
verified the absence of PAM protein in trunk extracts prepared
from homozygous PAM KO embryos (Fig. 5C). Radioimmu-
noassays specific for amidated CCK-8 and amidated PACAP
were not sensitive enough to detect expression of these
peptides in wildtype embryos of this age, precluding their
use to assess amidation in KO mice (not shown). Assays for
total AM (amidated and non-amidated) did show a significant
increase in levels of AM in the trunks of KO embryos (Fig.
5D), which we interpret as a possible compensatory response to
the lack of amidated AM in PAM KO embryos.
BrdU immunohistochemistry
PACAP, an amidated peptide, is found in differentiated
neurons throughout the CNS at least as early as e12 and is
thought to be an inhibitor of mitosis in the developing cortex
(Lu and DiCicco-Bloom, 1997; Suh et al., 2001). Cells located
in the proliferative region adjacent to PACAP-positive cells
express both PAM and the PACAP receptor (PAC 1), consistent
with possible paracrine regulation of PACAP function by PAM
(Dicicco-Bloom et al., 1998). We used BrdU to label cells
undergoing DNA synthesis and found that there were no
differences in the labeling index of e12.5 mutant PAM embryos
as compared to littermate controls in the telencephalon (Fig. 6),
diencephalon and metencephalon brain regions or in the spinal
cord. Furthermore, the number of BrdU-positive cells and the
total cell numbers in the brain and spinal cord of mutant
embryos were not changed at this stage (not shown).
Additionally, there were no differences in labeling indices in
the telencephalon and diencephalon regions in e13.5 PAM
mutant embryos as compared to wildtype controls. Taken
together, the data suggest that neuronal cell proliferation is
normal in the absence of PAM. The overall morphology and
cellular structure of all brain regions analyzed in mutant PAM
embryos appeared normal, suggesting that amidated peptides
may not be required for CNS development at e13.5 or earlier in
the mouse.
Characterization of PAM heterozygous mice
Mice heterozygous for the mutant PAM allele are viable and
fertile and show no gross motor abnormalities. Analysis of
peptide amidation activity in adult heterozygous mice showed
that heterozygotes have approximately one half the levels of
PHM (Fig. 7A) and PAL (Fig. 7B) activity, as well as about one
half the PAM protein levels in the atria as compared to wildtype
Fig. 5. Amidation activity and PAM protein are undetectable in PAM mutant embryos, while total AM levels are upregulated. PAM activity in both the heads and
trunks of e12.5 embryos was analyzed. No PHM (A) or PAL (B) activity was detected in PAM homozygous mutants. There was approximately 1/2 the activity level
of both PHM and PAL in PAM heterozygous embryos as compared to wildtype controls, as would be expected if there were no compensatory upregulation of PAM
in heterozygotes. Shown in panel C is the absence of any detectable PAM protein by Western blot analysis of the trunks of e14.5 homozygous mutant embryos using
an antibody that detects the full-length PAM protein (Ab 629) which is normally abundant in wildtype embryos at this age. To verify that equal amounts of protein
were loaded into each well, actin and g-adaptin levels were also determined (n = 4/, n = 8+/+, n = 7+/). Below is the PAM cDNA structure showing the
location of exon A. In panel D, assays for total AM using e14.5 trunks showed an increase in AM in the homozygous mutant mice (**P < 0.01 compared to the pool
of wildtype and heterozygous mice).
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the levels of PAM protein in both the cortex and pituitary (not
shown). Taken together, these data are consistent with the
hypothesis that the PAM gene encodes all peptide amidation
enzymatic activity in the adult mouse and that no compensatory
increase in expression occurs in heterozygous animals.Fig. 6. Cell proliferation is unaltered in the CNS of e12.5 mutant PAM embryos.
Shown in panels A and C are the results of immunohistochemical analysis on
transverse sections (10 Am) of the telencephalon of e12.5 wildtype and PAM
mutant embryos that were incubated with a BrdU polyclonal antibody (brown)
and counterstained with methyl green. When the primary antibody was omitted,
no staining was obtained (B, D). The average labeling indices for wildtype and
homozygous mutants were 22.5% and 23.3%, respectively, in the telencephalon.
The scale bar represents 100 Am in panels A–D. No significant differences were
found in the labeling index in any of the CNS regions analyzed.Since several peptides involved in nociception are known
to be amidated, we compared the response of PAM heterozy-
gous mice to that of wildtype controls in the tail-flick assay
and determined that heterozygous mice had similar tail-flick
latencies in response to a radiant heat source as compared to
wildtype controls (+/+4.7 s, n = 10; +/4.4 s, n = 8, P =
0.60). Furthermore, there were no differences in the weights of
male outbred PAM heterozygotes at 2 months (P = 0.32) (Fig.
7D), 10 months (P = 0.70) or 2 years of age (P = 0.61) as
compared to age-matched littermate controls. We also deter-
mined that there were no significant differences in the weights
of female heterozygotes at 2 months, 7 months and 18 months
after birth as compared to age-matched controls. In addition,
the weights of congenic 129S6 PAM heterozygous and
wildtype littermates were determined during the first postnatal
months as well as at selected ages through 10 months; again,
no difference was seen between genotypes. These data
indicate that there are no alterations in total body weight in
PAM heterozygous mice. However, 10-month-old 129S6 PAM
heterozygous mice showed an increased adiposity when
compared to age-matched littermate controls of similar total
body weight (+/7.6% T 0.8, n = 10; +/+5.4% T 1.5, n = 11;
P = 0.05). These results indicate that there may be deficits in
one or more amidated peptides involved in the regulation of
adiposity.
Several amidated peptides modulate glucose metabolism.
Therefore, we performed glucose tolerance tests on both 2-
month- and 10-month-old (aged) PAM heterozygous and
wildtype mice. There were no differences in blood glucose
Fig. 7. Adult PAM heterozygous mice appear behaviorally normal although
they have only half the wildtype PAM levels. (A and B) There are one half the
activity levels of both PHM (A) and PAL (B) in the atria of PAM heterozygous
mice (n = 5 per genotype). (C) PAM-1 protein levels were significantly reduced
in the atria of heterozygous mice. Each lane represents 10 Ag protein. Films
were photographed with a digital camera, and density was determined using
NIH Image. The results of an unpaired t test are shown (n = 5 per genotype).
(D) Shown is a comparison of heterozygous weights at 2 months of age as
compared to wildtype controls. There is no difference in total body weight
between the two groups. (E) Shown are the results of a glucose tolerance test in
2-month-old PAM heterozygous and wildtype mice after a 6-h fast. There were
no differences in blood glucose levels at any time point. (F) Shown are the
results of a glucose tolerance test in 10-month-old PAM heterozygous mice as
compared to wildtype controls. The blood glucose levels of PAM heterozygous
mice are significantly increased at 60 and 120 min after an i.p. injection of d-
glucose (*P = 0.006, **P = 0.02). It should be noted that the elevated blood
glucose levels of the heterozygotes at 30 min approached significance (P =
0.057). (G and H) Shown are the ratios of amidated CCK to total NPY in
postnatal hypothalamus (n = 12+/, n = 9+/+) (G) and in the adult
hypothalamus (n = 14+/, n = 8+/+) (H). While there are no detectable
differences in the levels of several amidated peptides in adult PAM
heterozygous mice, there are slight reductions in amidated peptide levels in
early postnatal heterozygous mice. Error bars represent TSEM.
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F). While there were no significant differences in blood
glucose levels at any time point after glucose challenge in 2-
month-old PAM heterozygotes (Fig. 7E), aged PAM hetero-
zygous mice had significantly elevated blood glucose levels
at 60 min (P = 0.006) and 120 min (P = 0.02) post-injection
(Fig. 7F). Similar results were obtained in PAM heterozy-
gous mice on both C57Bl6/129SvEv outbred and 129S6
congenic backgrounds.
To begin to determine if one half of the normal level of
amidating enzyme activity is sufficient to amidate peptides to
the wildtype level, we compared the amounts of amidated and
non-amidated peptides by RIA analysis of pituitary and
hypothalamic extracts from early postnatal and adult hetero-
zygous and wildtype mice. There were no significant
differences in the ratios of amidated a-MSH to ACTH (1–
39) (P = 0.11) and amidated JP to ACTH (1–39) (P = 0.13) in
the pituitary of p3 heterozygous mice as compared to
littermate controls or in the ratio of amidated CCK to NPY
in the hypothalamus (P = 0.18) (Fig. 7G). Although not
significant, there was a noticeable trend for the ratios of the
postnatal heterozygotes to be lower, suggesting that there may
be a slight decrease in the production of amidated peptides in
these younger mice. In the adult, there were no detectable
differences in the ratios of amidated a-MSH to ACTH (1–39)
(P = 0.11) and amidated JP to ACTH (1–39) (P = 0.98) in
the pituitary as compared to littermate controls or in the ratio
of amidated CCK to NPY in the hypothalamus (P = 0.78)
(Fig. 7H).
Discussion
PAM is the sole source of peptide amidating enzymatic activity
in the mouse
Early immunohistochemical studies raised the possibility
that there might be an alternative peptide amidation
mechanism since PP cells in the pancreas (Martinez et al.,
1993a) and epithelial cells of the small intestine (Martinez et
al., 1993b) contain amidated substrates but no detectable
PAM. Our data indicate that the PAM gene is the sole
source of peptide amidating activity in the mouse embryo
since amidation activity was completely absent from
homozygous mutants prior to death. This finding is
consistent with the absence of an alternative amidation
mechanism in Drosophila, where a loss of PHM activity
results in embryonic lethality at midgestation (Kolhekar et
al., 1997b). Both during embryonic development and as
adults, PAM heterozygous mice have one half the amidation
activity of wildtype mice. Thus, we conclude that PAM is
almost certainly exclusively responsible for amidating all
peptide hormones capable of serving as substrates in
midgestational embryos. It is possible that a minor amidation
enzyme could be upregulated in late gestational embryos and
in the adult mouse in the complete absence of PAM. A
conditional PAM mutant will be needed to test this
possibility.
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development
We have found that deletion of PAM produces an
embryonic lethal phenotype that appears to result from
cardiovascular deficits. Furthermore, lethality occurs between
e14.5 and e15.5 which corresponds to the time when the
architecture of the fetal circulatory system is completed
(Rugh, 1968). It is unlikely that PAM enzymatic activity is
involved directly in the formation of the heart because
cardiac muscle contraction (e8) and cardiac looping (e10)
(Rugh, 1968) both occur well before the onset of edema by
e12.5 (Fig. 2). Furthermore, we found no evidence for
obvious histological defects during morphogenesis of the
heart in PAM KO mice. However, the first detectable
evidence of a PAM KO phenotype occurs at the onset of
the developmental process of vasculature remodeling, a
process whereby the rudimentary six aortic arches are
remodeled to form the dorsal aorta, the common carotids
and the pulmonary artery (Gilbert, 1991). Therefore, we
believe that the phenotype of the PAM KO is most consistent
with a severe CV functional deficit rather than a morphoge-
netic defect in heart formation.
There are several notable differences when one com-
pares the PAM KO with mice lacking the transcription
factors retinoid X receptor alpha (RXR-a) (Sucov et al.,
1994) and notch 2 (McCright et al., 2001), two KO
mouse strains exhibiting prenatal edema. First, the edema
in these models is not as severe as that seen in mutant
PAM embryos and suggests that the CV deficits in PAM
mutant embryos are more extensive and distinct from these
other mouse strains. Secondly, we see an increase in the
density in trabeculae carneae in the left ventricles as early
as e12.5 in homozygous PAM mutants (Fig. 4). This
increase is similar to the hypertrophy seen in hypertensive
states in both mouse and human (Chien et al., 1991;
Oliver et al., 1997; Sugden and Clerk, 1998; Yang et al.,
1999; Chien and Olson, 2002) and provides further
evidence that the PAM mutant phenotype is due to a
functional deficit in the CV system. In contrast, these
other KO mice have thin ventricular walls most likely due
to a lack of expansion of cardiac myocytes. Mutant PAM
embryos, therefore, may be a novel model to study CV
disease in the embryo.
At this point, we cannot entirely rule out the possibility that
a disruption of salt balance or fluid excretion, in addition to CV
deficits, is contributing to the edema seen in mutant PAM
embryos. However, the adrenal glands and kidneys are still
functionally rudimentary between e12.5 and e14.5 when
mutant PAM embryos first begin to show edema and when
they die, respectively, and thus are unlikely to contribute
significantly to fluid homeostasis at midgestational ages. At
early embryonic ages, the heart probably also functions as an
endocrine organ excreting circulating hormones such as AM
and atrial natriuretic factor (ANF) that can also affect both
blood pressure and salt balance (Kitamura et al., 2002).
Therefore, it is possible that the severe edema seen in PAMmutants could partially be due to hormonal deregulation of
fluid homeostasis.
The PAM KO phenotype is a phenocopy of adrenomedullin
gene disruption
Mouse KO models exist for several amidated peptides.
However, only mice containing mutations in the adrenome-
dullin (AM) gene die as early in gestation as PAM mutants.
The AM gene encodes two potent vasodilators, pro-amino
terminal peptide (PAMP) and adrenomedullin (reviewed in Eto,
2001) that absolutely require amidation for binding to their
receptors in vitro (Eguchi et al., 1994; Iwasaki et al., 1996).
Two mouse KO models of AM lack both PAMP and AM
peptides (Caron and Smithies, 2001; Shindo et al., 2001), and
one lacks the AM peptide only leaving PAMP intact (Hay and
Smith, 2001; Shimosawa et al., 2002). All three mutant strains
are lethal by midgestation. Deletion of both peptides results in
a slightly more severe phenotype than when AM only is
deleted, indicating that both AM and PAMP have at least some
non-redundant functions.
There are striking similarities between the phenotypes of
PAM KO and AM KO mice. The time of lethality and the
severity of the edema of the PAM KO are similar to that
observed in the AM KO. Several other characteristics of the
PAM KO including poorly developed yolk sac vasculature
(Fig. 2), thinning of multiple arterial structures (Fig. 3) and
increased trabeculation in the left ventricles (Fig. 4) are also
similar to the phenotype of the AM gene KOs (Caron and
Smithies, 2001; Shindo et al., 2001). We therefore believe
that most, if not all, of the phenotype of the PAM mutant is
due to a lack of amidated AM hormones. Assays for total
AM in PAM KO embryos revealed increased levels of this
immunoreactivity, perhaps reflecting a compensatory increase
in basal AM expression and/or a lack of feedback inhibition.
Importantly, no evidence was found for any moderation of
the AM KO phenotype which might be expected if an
alternate mechanism could amidate AM-derived peptides.
Although we did observe edema in PAM embryos earlier
than has been reported for the AM KO, a more detailed
comparative analysis of the two KO strains will be needed to
determine if the sole cause of the PAM KO phenotype is the
lack of functional AM peptides. If there were differences,
this would suggest that PAM function extends beyond that of
being an indirect CV regulator by conferring activity to AM
peptides. It can be speculated that, because mutant PAM
embryos lack functional AM peptides, they are hypertensive.
This eventually leads to the ventricular hypertrophy observed
in PAM mutant embryos.
At this time, it is unclear if amidated AM peptides or PAM
activity is required for CV function in late gestation and in
adulthood to the extent that they are required during
midgestational ages. By temporally restricting deletion of
PAM, it may be possible to bypass the absolute requirement
for PAM and AM peptides during midgestation. Furthermore, it
would allow us to determine if PAM or other amidated peptides
besides AM have potential CV regulatory functions.
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neuronal cell proliferation
The high expression of PAM in the ventricular zone
regions of the telencephalon, diencephalon, metencephalon
and spinal cord, adjacent to regions where PACAP expression
is also high, suggested that PAM expressed on the cell surface
might regulate neuronal cell proliferation by activating non-
amidated PACAP peptides secreted from adjacent post-mitotic
cells (Dicicco-Bloom et al., 1998). However, we found no
difference in neuronal precursor proliferation in several CNS
regions of mutant PAM embryos at e12.5 or e13.5 as
compared to littermate controls. The data are the first to
examine the rate of neurogenesis in an in vivo model where
there is a specific loss of amidated PACAP27 and PACAP38,
the two biologically active forms of PACAP (Sherwood et al.,
2000). Our finding of a lack of effect on cell proliferation
after deletion of PAM suggests that any effects of these
amidated forms of PACAP on proliferation are minimal, at
least at the midgestational ages examined. An alternative
possibility is that the potential effect of PACAP on
proliferation does not require amidation. PACAP KO mice
have been generated (Hashimoto et al., 2001; Hamelink et al.,
2002). Although the rate of cell proliferation has not been
measured directly yet in these mice, these mice have several
behavioral deficits including hyperactivity in an open field
test, suggesting that there is abnormal brain function and/or
structure. Because these mice lack both amidated and non-
amidated forms of PACAP peptides, it cannot be determined
which deleted forms of PACAP are contributing to the
phenotype of this mouse strain. Our data suggest that either
COOH-terminal glycine extended PACAP or other non-
amidated factors may be essential for neuronal proliferation
at midgestational ages.
A comparison of the phenotype of PAM KO mice and other
processing enzymes
The phenotype of the PAM KO mouse raises several
questions concerning neuropeptide processing. Since PAM is
the last step in the biosynthetic pathway, it was expected that
the phenotype of a PAM KO mouse might be no more severe
than those of the prohormone convertase and carboxypeptidase
KOs that function in the preceding steps of the processing
pathway (Czyzyk et al., 2003). Of the endoproteases, only furin
(Roebroek et al., 1998) and PACE4 (Constam and Robertson,
2000) deletions have resulted in embryonic lethality, with the
furin KO having the most severe phenotype with death at e10.5
with heart and axial rotation defects. Embryonic expression of
furin (Zheng et al., 1994; Roebroek et al., 1998) most closely
mimics that of PAM (Zhang et al., 1997), with both its early
onset and high expression in the heart and in several other
peripheral structures. Since proAM is most likely cleaved by
furin as evidenced by its furin consensus sequence (Ishimitsu et
al., 1994), it is interesting to speculate that a temporally
restricted KO of furin that could bypass the early embryonic
requirement for nodal (Roebroek et al., 1998; Beck et al., 2002)might share a similar phenotype to that of both the AM and
PAM KO mouse strains.
A naturally occurring point mutation in the gene for
carboxypeptidase E (CPEfat/CPEfat) results in a loss of CPE
function. Adult KO mice have severe obesity, hyperglycemia
and infertility (Naggert et al., 1995; Fricker et al., 1996). A KO
mouse for CPD, a carboxypeptidase (CP) believed to be a
potential candidate for redundant CP function (Fricker and
Leiter, 1999), has yet to be generated. However, a CPD KO
mouse is unlikely to have a phenotype much more severe than
that of CPEfat/CPEfat mice as the overall expression patterns are
similar for the two CPs at least in adult neuroendocrine tissues
(Dong et al., 1999). The question remains what is the CP that is
responsible for cleaving basic residues at the COOH-terminus
to expose the glycine substrate for PAM in the heart.
PAM heterozygous mice develop mild glucose intolerance in
the absence of altered amidated peptide levels
Radioimmunological analysis in both the central nervous
system and pituitary indicate no significant disruption in the
extent of amidation of several substrates in adult PAM
heterozygotes. For example, we found that the relative levels
of amidated a-MSH and JP in the pituitary compared to
unamidated forms are unaltered in adult mice. We also found
that the levels of amidated CCK in the hypothalamus were
unaltered in these mice. These data are consistent with previous
in vitro work showing that decreased peptide amidation was
seen only when PAM activity was reduced more than 2-fold
(Mains et al., 1991). Under basal conditions, our data suggest
that 50% of wildtype amidation activity is sufficient to amidate
most glycine-extended substrates in the mouse.
Several tests were used to assess alterations in processes that
are normally influenced by amidated peptides in PAM
heterozygous mice. Heterozygous mice did not differ in fasting
blood glucose levels at any age tested, while aged heterozygous
mice had significantly elevated blood glucose levels 60 and
120 min after an i.p. injection of d-glucose as compared to
littermate controls (Fig. 7F). These data raise the possibility
that there are regional and peptide-specific alterations in
amidated peptide levels in adult PAM heterozygous mice that
affect physiology, especially when the system is perturbed. For
example, amidated glucagon-like peptide 1 (GLP-1) which
normally functions to lower blood glucose levels (Scrocchi
et al., 1996) may be functionally impaired in PAM hetero-
zygotes. Our own observations support such peptide-specific
changes as we found that amidated PACAP38 was significantly
increased in the hypothalamus of adult heterozygotes (T.A.
Czyzyk, unpublished observations) but that levels of amidated
CCK8 were unchanged in the same region (Figs. 7G, H).
Alternatively, this disruption of glucose homeostasis could be
secondary to structural abnormalities such as increased
adiposity that could lead to insulin insensitivity. This possibil-
ity is supported by the increased adiposity of aged PAM
heterozygous mice. It is not clear why younger heterozygotes
show no evidence of altered glucose homeostasis, but one
possibility is that PAM heterozygous mice have general
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peptides that could eventually lead to a disruption of several
organs including the pancreas with subsequent effects on body
composition and metabolism.
Several factors could influence amidated peptide levels,
including dietary copper and ascorbate (reviewed in Prigge
et al., 2000). Probably more important is the amount of
glycine-extended substrate relative to the amount of PAM
enzyme. It would be expected that amidated peptide levels
would only be reduced if PAM were the rate-limiting factor
(that is, there is more substrate than enzyme activity). Although
we found no detectable changes in several amidated peptide
levels in adult mice, we did notice a decline in amidated
peptide levels in early postnatal PAM heterozygous mice.
There is much less PAM present at this time than in the adult
and is consistent with our findings. Therefore, at earlier
postnatal (and possibly embryonic stages), the levels of PAM
enzymatic activity may be the rate-limiting factor in the
biosynthesis of amidated peptides in heterozygous mice.
Acknowledgments
Supported by NIH grants DA08622 (JP) and DK32949
(BE), T32 MH/AG-19957 (TC) and a New Jersey State
Commission on Cancer Research predoctoral fellowship No.
700-043 (TC). The authors would like to thank Dr. Alwin
Schuller for technical guidance in gene targeting and Tracey
Hand for the PAM genomic clone used in making the targeting
vector.
References
Beck, S., Le Good, J.A., Guzman, M., Ben Haim, N., Roy, K., Beermann, F.,
Constam, D.B., 2002. Extraembryonic proteases regulate Nodal signalling
during gastrulation. Nat. Cell Biol. 4, 981–985.
Braas, K.M., Stoffers, D.A., Eipper, B.A., May, V., 1989. Tissue specific
expression of rat peptidylglycine alpha-amidating monooxygenase activity
and mRNA. Mol. Endocrinol. 3, 1387–1398.
Braas, K.M., Harakall, S.A., Ouafik, L., Eipper, B.A., May, V., 1992.
Expression of peptidylglycine alpha-amidating monooxygenase: an in
situ hybridization and immunocytochemical study. Endocrinology 130,
2778–2788.
Bradbury, A.F., Smyth, D.G., 1987. Biosynthesis of the C-terminal amide in
peptide hormones. Biosci. Rep. 7, 907–916.
Bruzzaniti, A., Marx, R., Mains, R.E., 1999. Activation and routing of
membrane-tethered prohormone convertases 1 and 2. J. Biol. Chem. 274,
24703–24713.
Caron, K.M., Smithies, O., 2001. Extreme hydrops fetalis and cardiovascular
abnormalities in mice lacking a functional adrenomedullin gene. Proc. Natl.
Acad. Sci. U. S. A. 98, 615–619.
Chien, K.R., Olson, E.N., 2002. Converging pathways and principles in heart
development and disease: CV@CSH. Cell 110, 153–162.
Chien, K.R., Knowlton, K.U., Zhu, H., Chien, S., 1991. Regulation of cardiac
gene expression during myocardial growth and hypertrophy: molecular
studies of an adaptive physiologic response. FASEB J. 5, 3037–3046.
Ciccotosto, G.D., Schiller, M.R., Eipper, B.A., Mains, R.E., 1999. Induction of
integral membrane PAM expression in AtT-20 cells alters the storage and
trafficking of POMC and PC1. J. Cell Biol. 144, 459–471.
Ciccotosto, G.D., Hand, T.A., Mains, R.E., Eipper, B.A., 2000. Breeding stock-
specific variation in peptidylglycine alpha-amidating monooxygenase
messenger ribonucleic acid splicing in rat pituitary. Endocrinology 141,
476–486.Constam, D.B., Robertson, E.J., 2000. SPC4/PACE4 regulates a TGFbeta
signaling network during axis formation. Genes Dev. 14, 1146–1155.
Cupples, W.A., 2002. Regulation of body weight. Am. J. Physiol.: Regul.,
Integr. Comp. Physiol. 282, R1264–R1266.
Czyzyk, T.A., Morgan, D.J., Peng, B., Zhang, J., Karantzas, A., Arai, M.,
Pintar, J.E., 2003. Targeted mutagenesis of processing enzymes and
regulators: implications for development and physiology. J. Neurosci.
Res. 74, 446–455.
Cuttitta, F., 1993. Peptide amidation: signature of bioactivity. Anat. Rec. 236,
87–93.
Dicicco-Bloom, E., Lu, N., Pintar, J.E., Zhang, J., 1998. The PACAP
ligand/receptor system regulates cerebral cortical neurogenesis. Ann. N. Y.
Acad. Sci. 865, 274–289.
Dong, W., Fricker, L.D., Day, R., 1999. Carboxypeptidase D is a potential
candidate to carry out redundant processing functions of carboxypeptidase
E based on comparative distribution studies in the rat central nervous
system. Neuroscience 89, 1301–1317.
Drucker, D.J., 2002. Biological actions and therapeutic potential of the
glucagon-like peptides. Gastroenterology 122, 531–544.
Eguchi, S., Hirata, Y., Iwasaki, H., Sato, K., Watanabe, T.X., Inui, T., Nakajima,
K., Sakakibara, S., Marumo, F., 1994. Structure–activity relationship of
adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular
smooth muscle cells. Endocrinology 135, 2454–2458.
Eipper, B.A., Park, L., Keutmann, H.T., Mains, R.E., 1986. Amidation of
joining peptide, a major pro-ACTH/endorphin-derived product peptide.
J. Biol. Chem. 261, 8686–8694.
Eipper, B.A., Stoffers, D.A., Mains, R.E., 1992. The biosynthesis of
neuropeptides: peptide alpha-amidation. Annu. Rev. Neurosci. 15, 57–85.
Eto, T., 2001. A review of the biological properties and clinical implications of
adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP),
hypotensive and vasodilating peptides. Peptides 22, 1693–1711.
Eto, T., Samson, W.K., 2001. Adrenomedullin and proadrenomedullin N-
terminal 20 peptide: vasodilatory peptides with multiple cardiovascular and
endocrine actions. Trends Endocrinol. Metab. 12, 91–93.
Fricker, L.D., Leiter, E.H., 1999. Peptides, enzymes and obesity: new insights
from a Fdead_ enzyme. Trends Biochem. Sci. 24, 390–393.
Fricker, L.D., Berman, Y.L., Leiter, E.H., Devi, L.A., 1996. Carboxypeptidase
E activity is deficient in mice with the fat mutation. Effect on peptide
processing. J. Biol. Chem. 271, 30619–30624.
Garayoa, M., Bodegas, E., Cuttitta, F., Montuenga, L.M., 2002. Adrenome-
dullin in mammalian embryogenesis. Microsc. Res. Tech. 57, 40–54.
Gilbert, S.F., 1991. Developmental Biology. Sinauer Associates, Sunderland,
MA.
Grimes, A., Hearn, C.J., Lockhart, P., Newgreen, D.F., Mercer, J.F., 1997.
Molecular basis of the brindled mouse mutant (Mo(br)): a murine model of
Menkes disease. Hum. Mol. Genet. 6, 1037–1042.
Grimmelikhuijzen, C.J., Leviev, I., Carstensen, K., 1996. Peptides in the
nervous systems of cnidarians: structure, function, and biosynthesis. Int.
Rev. Cytol. 167, 37–89.
Gundlach, A.L., 2002. Galanin/GALP and galanin receptors: role in central
control of feeding, body weight/obesity and reproduction? Eur. J.
Pharmacol. 440, 255–268.
Hamelink, C., Tjurmina, O., Damadzic, R., Young, W.S., Weihe, E., Lee, H.W.,
Eiden, L.E., 2002. Pituitary adenylate cyclase-activating polypeptide is a
sympathoadrenal neurotransmitter involved in catecholamine regulation and
glucohomeostasis. Proc. Natl. Acad. Sci. U. S. A. 99, 461–466.
Han, M., Park, D., Vanderzalm, P.J., Mains, R.E., Eipper, B.A., Taghert, P.H.,
2004. Drosophila uses two distinct neuropeptide amidating enzymes,
dPAL1 and dPAL2. J. Neurochem. 90, 129–141.
Hansel, D.E., Eipper, B.A., Ronnett, G.V., 2001a. Neuropeptide Y functions as
a neuroproliferative factor. Nature 410, 940–944.
Hansel, D.E., May, V., Eipper, B.A., Ronnett, G.V., 2001b. Pituitary adenylyl
cyclase-activating peptides and alpha-amidation in olfactory neurogenesis
and neuronal survival in vitro. J. Neurosci. 21, 4625–4636.
Hashimoto, H., Shintani, N., Tanaka, K., Mori, W., Hirose, M., Matsuda, T.,
Sakaue, M., Miyazaki, J., Niwa, H., Tashiro, F., Yamamoto, K., Koga, K.,
Tomimoto, S., Kunugi, A., Suetake, S., Baba, A., 2001. Altered
psychomotor behaviors in mice lacking pituitary adenylate cyclase-
T.A. Czyzyk et al. / Developmental Biology 287 (2005) 301–313312activating polypeptide (PACAP). Proc. Natl. Acad. Sci. U. S. A. 98,
13355–13360.
Hay, D.L., Smith, D.M., 2001. Knockouts and transgenics confirm the
importance of adrenomedullin in the vasculature. Trends Pharmacol. Sci.
22, 57–59.
In, Y., Fujii, M., Sasada, Y., Ishida, T., 2001. Structural studies on C-amidated
amino acids and peptides: structures of hydrochloride salts of C-amidated
Ile, Val, Thr, Ser, Met, Trp, Gln and Arg, and comparison with their C-
unamidated counterparts. Acta Crystallogr., Sect. B: Struct. Sci. 57, 72–81.
Ishimitsu, T., Kojima, M., Kangawa, K., Hino, J., Matsuoka, H., Kitamura, K.,
Eto, T., Matsuo, H., 1994. Genomic structure of human adrenomedullin
gene. Biochem. Biophys. Res. Commun. 203, 631–639.
Iwasaki, H., Hirata, Y., Iwashina, M., Sato, K., Marumo, F., 1996. Specific
binding sites for proadrenomedullin N-terminal 20 peptide (PAMP) in the
rat. Endocrinology 137, 3045–3050.
Jiang, N., Kolhekar, A.S., Jacobs, P.S., Mains, R.E., Eipper, B.A., Taghert, P.H.,
2000. PHM is required for normal developmental transitions and for
biosynthesis of secretory peptides in Drosophila. Dev. Biol. 226, 118–136.
Kaldany, R.R., Nambu, J.R., Scheller, R.H., 1985. Neuropeptides in identified
Aplysia neurons. Annu. Rev. Neurosci. 8, 431–455.
Karaplis, A.C., Luz, A., Glowacki, J., Bronson, R.T., Tybulewicz, V.L.,
Kronenberg, H.M., Mulligan, R.C., 1994. Lethal skeletal dysplasia from
targeted disruption of the parathyroid hormone-related peptide gene. Genes
Dev. 8, 277–289.
Kitamura, K., Kangawa, K., Eto, T., 2002. Adrenomedullin and PAMP:
discovery, structures, and cardiovascular functions. Microsc. Res. Tech. 57,
3–13.
Kolhekar, A.S., Mains, R.E., Eipper, B.A., 1997a. Peptidylglycine alpha-
amidating monooxygenase: an ascorbate-requiring enzyme. Methods
Enzymol. 279, 35–43.
Kolhekar, A.S., Roberts, M.S., Jiang, N., Johnson, R.C., Mains, R.E., Eipper,
B.A., Taghert, P.H., 1997b. Neuropeptide amidation in Drosophila:
separate genes encode the two enzymes catalyzing amidation. J. Neurosci.
17, 1363–1376.
Kuo, Y.M., Zhou, B., Cosco, D., Gitschier, J., 2001. The copper transporter
CTR1 provides an essential function in mammalian embryonic develop-
ment. Proc. Natl. Acad. Sci. U. S. A. 98, 6836–6841.
Lee, K., Deeds, J.D., Segre, G.V., 1995. Expression of parathyroid hormone-
related peptide and its receptor messenger ribonucleic acids during fetal
development of rats. Endocrinology 136, 453–463.
Lu, N., DiCicco-Bloom, E., 1997. Pituitary adenylate cyclase-activating
polypeptide is an autocrine inhibitor of mitosis in cultured cortical precursor
cells. Proc. Natl. Acad. Sci. U. S. A. 94, 3357–3362.
Mains, R.E., Bloomquist, B.T., Eipper, B.A., 1991. Manipulation of neuropep-
tide biosynthesis through the expression of antisense RNA for peptidylgly-
cine alpha-amidating monooxygenase. Mol. Endocrinol. 5, 187–193.
Martinez, A., Montuenga, L.M., Springall, D.R., Treston, A., Cuttitta, F., Polak,
J.M., 1993a. Immunocytochemical localization of peptidylglycine alpha-
amidating monooxygenase enzymes (PAM) in human endocrine pancreas.
J. Histochem. Cytochem. 41, 375–380.
Martinez, A., Burrell, M.A., Kuijk, M., Montuenga, L.M., Treston, A., Cuttitta,
F., Polak, J.M., 1993b. Localization of amidating enzymes (PAM) in rat
gastrointestinal tract. J. Histochem. Cytochem. 41, 1617–1622.
McCright, B., Gao, X., Shen, L., Lozier, J., Lan, Y., Maguire, M., Herzlinger,
D., Weinmaster, G., Jiang, R., Gridley, T., 2001. Defects in development of
the kidney, heart and eye vasculature in mice homozygous for a
hypomorphic Notch2 mutation. Dev. Suppl. 128, 491–502.
Merkler, D.J., 1994. C-terminal amidated peptides: production by the in vitro
enzymatic amidation of glycine-extended peptides and the importance of
the amide to bioactivity. Enzyme Microb. Technol. 16, 450–456.
Montuenga, L.M., Martinez, A., Miller, M.J., Unsworth, E.J., Cuttitta, F., 1997.
Expression of adrenomedullin and its receptor during embryogenesis
suggests autocrine or paracrine modes of action. Endocrinology 138,
440–451.
Mueller, G.P., Husten, E.J., Mains, R.E., Eipper, B.A., 1993. Peptide alpha-
amidation and peptidylglycine alpha-hydroxylating monooxygenase: con-
trol by disulfiram. Mol. Pharmacol. 44, 972–980.
Naggert, J.K., Fricker, L.D., Varlamov, O., Nishina, P.M., Rouille, Y., Steiner,D.F., Carroll, R.J., Paigen, B.J., Leiter, E.H., 1995. Hyperproinsulinaemia
in obese fat/fat mice associated with a carboxypeptidase E mutation which
reduces enzyme activity. Nat. Genet. 10, 135–142.
Nassel, D.R., 1999. Tachykinin-related peptides in invertebrates: a review.
Peptides 20, 141–158.
Ogonowski, A.A., May, S.W., Moore, A.B., Barrett, L.T., O’Bryant, C.L.,
Pollock, S.H., 1997. Antiinflammatory and analgesic activity of an inhibitor
of neuropeptide amidation. J. Pharmacol. Exp. Ther. 280, 846–853.
Oliver, P.M., Fox, J.E., Kim, R., Rockman, H.A., Kim, H.S., Reddick, R.L.,
Pandey, K.N., Milgram, S.L., Smithies, O., Maeda, N., 1997. Hypertension,
cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide
receptor A. Proc. Natl. Acad. Sci. U. S. A. 94, 14730–14735.
Ouafik, L.H., Stoffers, D.A., Campbell, T.A., Johnson, R.C., Bloomquist, B.T.,
Mains, R.E., Eipper, B.A., 1992. The multifunctional peptidylglycine
alpha-amidating monooxygenase gene: exon/intron organization of cata-
lytic, processing, and routing domains. Mol. Endocrinol. 6, 1571–1584.
Prigge, S.T., Mains, R.E., Eipper, B.A., Amzel, L.M., 2000. New insights into
copper monooxygenases and peptide amidation: structure, mechanism and
function. Cell. Mol. Life Sci. 57, 1236–1259.
Roebroek, A.J., Umans, L., Pauli, I.G., Robertson, E.J., van Leuven, F., Van de
Ven, W.J., Constam, D.B., 1998. Failure of ventral closure and axial
rotation in embryos lacking the proprotein convertase Furin. Development
125, 4863–4876.
Rugh, R., 1968. The Mouse. Its Reproduction and Development. Burgess
Publishing, Minneapolis, MI.
Schafer, M.K., Stoffers, D.A., Eipper, B.A., Watson, S.J., 1992. Expression of
peptidylglycine alpha-amidating monooxygenase (EC 1.14.17.3) in the rat
central nervous system. J. Neurosci. 12, 222–234.
Schnabel, E., Mains, R.E., Farquhar, M.G., 1989. Proteolytic processing of pro-
ACTH/endorphin begins in the Golgi complex of pituitary corticotropes
and AtT-20 cells. Mol. Endocrinol. 3, 1223–1235.
Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., Auerbach, A.B.,
Joyner, A.L., Drucker, D.J., 1996. Glucose intolerance but normal satiety in
mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat.
Med. 2, 1254–1258.
Seidah, N.G., Chretien, M., 1999. Proprotein and prohormone convertases: a
family of subtilases generating diverse bioactive polypeptides. Brain Res.
848, 45–62.
Sherwood, N.M., Krueckl, S.L., McRory, J.E., 2000. The origin and function of
the pituitary adenylate cyclase-activating polypeptide (PACAP)/glucagon
superfamily. Endocr. Rev. 21, 619–670.
Shimosawa, T., Shibagaki, Y., Ishibashi, K., Kitamura, K., Kangawa, K., Kato,
S., Ando, K., Fujita, T., 2002. Adrenomedullin, an endogenous peptide,
counteracts cardiovascular damage. Circulation 105, 106–111.
Shindo, T., Kurihara, Y., Nishimatsu, H., Moriyama, N., Kakoki, M., Wang, Y.,
Imai, Y., Ebihara, A., Kuwaki, T., Ju, K.H., Minamino, N., Kangawa, K.,
Ishikawa, T., Fukuda, M., Akimoto, Y., Kawakami, H., Imai, T., Morita, H.,
Yazaki, Y., Nagai, R., Hirata, Y., Kurihara, H., 2001. Vascular abnormalities
and elevated blood pressure in mice lacking adrenomedullin gene.
Circulation 104, 1964–1971.
Shuto, Y., Uchida, D., Onda, H., Arimura, A., 1996. Ontogeny of pituitary
adenylate cyclase activating polypeptide and its receptor mRNA in the
mouse brain. Regul. Pept. 67, 79–83.
Steiner, D.F., 1998. The proprotein convertases. Curr. Opin. Chem. Biol. 2,
31–39.
Steveson, T.C., Ciccotosto, G.D., Ma, X.M., Mueller, G.P., Mains, R.E., Eipper,
B.A., 2003. Menkes protein contributes to the function of peptidylglycine
alpha-amidating monooxygenase. Endocrinology 144, 188–200.
Sucov, H.M., Dyson, E., Gumeringer, C.L., Price, J., Chien, K.R., Evans, R.M.,
1994. RXR alpha mutant mice establish a genetic basis for vitamin A
signaling in heart morphogenesis. Genes Dev. 8, 1007–1018.
Sugden, P.H., Clerk, A., 1998. Cellular mechanisms of cardiac hypertrophy.
J. Mol. Med. 76, 725–746.
Suh, J., Lu, N., Nicot, A., Tatsuno, I., DiCicco-Bloom, E., 2001. PACAP is an
anti-mitogenic signal in developing cerebral cortex. Nat. Neurosci. 4,
123–124.
Taghert, P.H., 1999. FMRFamide neuropeptides and neuropeptide-associated
enzymes in Drosophila. Microsc. Res. Tech. 45, 80–95.
T.A. Czyzyk et al. / Developmental Biology 287 (2005) 301–313 313Yang, X.P., Liu, Y.H., Shesely, E.G., Bulagannawar, M., Liu, F., Carretero,
O.A., 1999. Endothelial nitric oxide gene knockout mice: cardiac
phenotypes and the effect of angiotensin-converting enzyme inhibitor on
myocardial ischemia/reperfusion injury. Hypertension 34, 24–30.
Zhang, J., Zheng, M., Eipper, B.A., Pintar, J.E., 1997. Embryonic and uterine
expression patterns of peptidylglycine alpha-amidating monooxygenasetranscripts suggest a widespread role for amidated peptides in development.
Dev. Biol. 192, 375–391.
Zheng, M., Streck, R.D., Scott, R.E., Seidah, N.G., Pintar, J.E., 1994. The
developmental expression in rat of proteases furin, PC1, PC2, and
carboxypeptidase E: implications for early maturation of proteolytic
processing capacity. J. Neurosci. 14, 4656–4673.
